Gene expression and DNA methylation are extensively coordinated with MRI-based brain microstructural characteristics

  • Chris GaiteriEmail author
  • Robert Dawe
  • Sara Mostafavi
  • Katherine D. Blizinsky
  • Shinya Tasaki
  • Vitalina Komashko
  • Lei Yu
  • Yanling Wang
  • Julie A. Schneider
  • Konstantinos Arfanakis
  • Philip L. De Jager
  • David A. Bennett
Open Access
Original Research


Cognitive function relies on both molecular levels and cellular structures. However, systematic relationships between these two components of cognitive function, and their joint contribution to disease, are largely unknown. We utilize postmortem neuroimaging in tandem with gene expression and DNA methylation, from 222 deeply-phenotyped persons in a longitudinal aging cohort. Expression of hundreds of genes and methylation at thousands of loci are related to the microstructure of extensive regions of this same set of brains, as assessed by MRI. The genes linked to brain microstructure perform functions related to cell motility, transcriptional regulation and nuclear processes, and are selectively associated with Alzheimer’s phenotypes. Similar methodology can be applied to other diseases to identify their joint molecular and structural basis, or to infer molecular levels in the brain on the basis of neuroimaging for precision medicine applications.


Alzheimer’s disease brain networks molecular networks gene expression MRI 


Molecular activity and brain structure influence each other (West and Greenberg 2011), and both affect cognitive function (Bishop et al. 2010). Progress towards a systematic molecular basis for neuroimaging findings indicates that regional volumes are shaped by genetic factors (Hibar et al. 2015), and that spatial patterns of gene expression correspond to cell type distributions (Krienen et al. 2016), structural (Fulcher and Fornito 2016) and functional connectivity patterns (Hawrylycz et al. 2015; Richiardi et al. 2015; Vértes et al. 2016; Wang et al. 2015). While these studies suggest that gene expression and aspects of brain microstructure have similar spatial patterns, it is unclear to what extent they covary within a particular brain region or across regions.

The relationships of molecular and neuroimaging features with brain disease or other phenotypes have been studied independently. For instance, identifying brain structures that covary with disease status is a common focus of neuroimaging. Likewise, identifying covariation of gene expression with disease status is a common focus of molecular biology. However, studies which span these two approaches to test the covariation of gene expression and brain structure are limited. Efforts to unite molecular biology with neuroimaging in the context of disease through “imaging genetics” have identified a small number of polymorphisms tied to variation in brain structures (Hibar et al. 2015; Munafò et al. 2008; Stein et al. 2012) including a subset of AD GWAS variants (Braskie et al. 2011; Erk et al. 2011; Kohannim et al. 2013; P. Zhang et al. 2015). However, variation in gene expression or other omics in the brain has not been measured concurrently with neuroimaging in the same set of persons. The increasing body of evidence that molecular maps of the brain correspond to structural and functional brain maps (Hawrylycz et al. 2015; Krienen et al. 2016; Richiardi et al. 2015), and the tight integration of gene expression and epigenetics with cellular function (Bishop et al. 2010; West and Greenberg 2011), indicate the potential for a unified “imaging omics” perspective on disease, using omics and imaging obtained from the same set of brains.

We followed an imaging omics approach to discover relationships between omics and neuroimaging, using ~200 brains with paired omics and ex-vivo neuroimaging (Dawe et al. 2014; Dawe et al. 2009; Dawe et al. 2016; Kotrotsou et al. 2014; Kotrotsou et al. 2015), from two longitudinal cohort studies of aging (A Bennett et al. 2012; Bennett et al. 2005). Our approach to finding relationships between brain omics and structure is analogous to typical neuroimaging studies and imaging genetics studies (Fig. 1). However, instead of using genetic polymorphisms, we use gene expression and methylation data generated from the dorsolateral-prefrontal cortex (DLPFC) as our molecular trait of interest, and map it onto the brain, just as traits are mapped to the brain in a typical neuroimaging study (overview and comparison of approach in Fig. 1).
Fig. 1

Schematic of imaging omics, a combination of brain omics and neuroimaging, with parallel methodology to other types of imaging studies.

The current study identifies brain regions whose microstructure (as measured by MRI) are associated with brain omics data, such as gene expression or methylation, in a manner parallel to typical neuroimaging studies

Previously we conducted expression-wide and methylation-wide association studies, testing for relationships to the transverse relaxation rate (R2) in cognition-associated brain regions, controlling for the effects of common age-related brain neuropathologies (Yu et al. 2017). We found four genes associated with R2, the inverse of T2. In the present study, we extend this prior work by examining molecular systems defined by DLPFC expression and methylation data in relation to a wide range of white-matter brain regions. We then use tractography to identify cortical regions connected via the white-matter regions and associated DLPFC molecular systems. Finally, we take the molecular systems that are related to brain microstructure, and examine their associations with AD clinical and pathologic traits. Based on these tests, we demonstrate the existence of several associations between molecular systems and brain microstructure. We map the spatial extent of these relationships, the genes involved and their functional characteristics, and the relevance of these imaging omics associations to common age-related neuropathologies and cognitive decline - the core clinical feature of AD.


Parent study and substudy characteristics

We evaluated data from two prospective cohort studies: the Religious Orders Study (ROS) (A Bennett et al. 2012), and the Rush Memory and Aging Project (MAP) (Bennett et al. 2005). ROS and MAP were designed to have consistent data acquisition and processing and are analyzed jointly in numerous publications (Arfanakis et al. 2016; Boyle et al. 2016; Buchman et al. 2012; Lim et al. 2017; Nag et al. 2015), and this extends to neuroimaging and omics assays acquired across both cohorts. ROS enrolls older religious clergy from across the United States since 1994, while MAP started in 1997 and enrolls older residents from Chicago-area retirement facilities and subsidized housing, and other older residents through church groups and social service agencies. The parent cohort studies and substudies were approved by Rush University Medical Center Institutional Review Boards. Participants provided written informed consent and all participants signed an Anatomic Gift Act for brain donation.

A subset of participants in ROS and MAP underwent postmortem structural neuroimaging. RNAseq and/or DNA methylation assays were performed on DLPFC brain tissue. Data from 222 participants were used in this study, with a mean age of 89.8, of which 153 were female. These participants exhibited a typical distribution of cognitive function for their age (mean MMSE proximate to death =19.5, median = 23). Full clinical and demographic characteristics are found in Table 1.
Table 1

Clinical characteristics of imaging omics cohort. Full classification criteria shown in supplementary data, and raw data available to download through


w/ RNAseq

w/ DNA methylation




age at death (mean, sd)

89.74 (6.10)

89.75 (5.96)

female (n, %)

114 (67.9)

153 (68.9)

years of education (mean, sd)

15.92 (3.52)

15.77 (3.59)

MMSE, last visit (mean, sd)

20.54 (9.35)

19.50 (9.68)

Clinical dementia (n, %)

75 (44.6)

112 (50.5)

MCI (n, %)

44 (26.2)

50 (22.5)

NCI (n, %)

49 (29.2)

60 (27.0)

AD (n, %)

70 (41.7)

106 (47.7)

Global AD pathology (mean, sd)

0.69 (0.60)

0.75 (0.62)

Amyloid score (mean, sd)

4.62 (4.45)

4.82 (4.52)

Tangles score (mean, sd)

6.43 (8.45)

6.89 (8.18)

Presence of gross infarctions (n, %)

53 (31.5)

72 (32.4)

Presence of microinfarcts (n, %)

46 (27.4)

57 (25.7)

Presence of Lewy bodies (n, %)

30 (17.9)

45 (20.3)

Neuropathology protocols

Details on clinical and neuropathological methods in ROS and MAP have been extensively published (Bennett et al. 2006b; Schneider et al. 2012; Schneider et al. 2004) and data access links are provided in supplementary methods. Due to their impact on structural brain imaging we assess levels of micro and macroscopic infarcts, β-amyloid load, paired helical filament (PHF) tau tangle density, and Lewy bodies in multiple brain regions. Neurofibrillary tangles were also quantified using Braak staging and neuritic plaque frequency, according the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Separately, a composite measure of plaques and tangles assesses global burden of AD pathology (Bennett et al. 2004). Details of all other neuropathology measures are shown in supplementary methods.

Cognitive function assessment and clinical diagnoses

Cognitive function in ROS and MAP participants is assessed annually along multiple dimensions with 21 cognitive tests. Seventeen tests are used to create composite scores of global cognition as well as five cognitive domains of episodic memory, semantic memory, working memory, perceptual speed and visuospatial abilities. Participants are evaluated by a clinician who used cognitive and clinical data to identify AD and other dementias. Detailed methods are published (R. Wilson et al. 2010; R. S. Wilson et al. 2015; R. S. Wilson et al. 2007) and are provided in Supplemental Methods. The clinical evaluation was done in a three stage process that involved a computer generated actuarial decision tree, followed by a clinical diagnosis by a neuropsychologist which identified the presence of cognitive impairment, followed by a clinician who identified the presence of dementia and its causes. MCI refers to those persons with cognitive impairment without dementia. Details have been previously published (Bennett et al. 2006a; Bennett et al. 2002). After death, a neurologist reviews all clinical data blind to pathologic data and makes a summary clinical diagnosis. Of the 222 participants in this substudy, 60 had no cognitive impairment, 49 had MCI, 106 had AD and 6 had other dementia.

Generation of RNAseq and methylation data

Details on RNAseq and methylation data are published (De Jager et al. 2014; Ng et al. 2017). Briefly, RNA from 168 individuals was extracted from DLPFC with the miRNeasy mini kit (Qiagen, Venlo, Netherlands) and the RNase free DNase Set (Qiagen, Vento, Netherlands). RNA concentration was quantified using Nanodrop (Thermo Fisher Scientific, Waltham, MA), and RNA quality was assessed using an Agilent Bioanalyzer. RNAseq was performed using Illumina HiSeq with 101 bp paired-end reads with an average depth of 90 m reads. The trimmed reads were aligned to the reference genome using Bowtie and the expression FPKM values were estimated using RSEM; see supplement for normalization details.

DNA from 222 individuals was extracted from DLPFC using the Qiagen QIAamp DNA mini protocol. DNA methylation data were generated using Illumina Infinium HumanMethylation450k Bead Chip assay. Raw data were further processed using Methylation Module v1.8 from the Illumina Genome Studio software suite to generate a beta value for each cytosine guanine dinucleotide (CpG); see supplement for normalization details.


Age is calculated from birth date and date of death; sex and years of education were self-reported from the baseline evaluation, and their effects were removed from the R2 signal with a linear model.

Omics data processing

For both gene expression and methylation, we follow the standard practice of reducing the dimensionality of gene expression and methylation, by collapsing them into a smaller number of molecular systems, identified via gene coexpression or comethylation. Gene coexpression is a standard methodology for identifying functionally related gene sets, in a manner that is strictly data-driven, and which can be related to any other phenotype recorded for the cohort, such as neuroimaging. This fundamental approach, which has now been used in numerous studies (Langfelder and Horvath 2008; B. Zhang and Horvath 2005), helps to identify more robust signals in gene expression data compared to single gene approaches, and reflects the activity of multiple regulatory mechanisms (Gaiteri et al. 2014). Coexpressed gene sets are sometimes referred to as “modules”, because they are detected as clusters in the gene-gene correlation matrix. The gene coexpression methodology has been extended to DNA methylation, identifying loci and nearby genes whose methylation level fluctuate in sync, across many subjects (Numata et al. 2012). To robustly identify coexpressed or comethylated gene sets, we use a consensus clustering method (Gaiteri et al. 2015) that operates on the gene-gene Pearson correlation matrix (or CPG-CPG correlation matrix) to find gene sets whose expression or methylation levels covary across subjects. Average levels of these 47 gene and 58 methylation sets were then related to neuroimaging in the same cohort as described below.

Neuroimaging data processing

Ex-vivo MRI scans show high correlation with antemortem imaging (Dawe et al. 2016) and were conducted on a 3 Tesla MRI scanner using a 2D fast spin-echo sequence with multiple echo-times (TEs), producing estimates of relaxation rates (R2) for each voxel. R2 values are the inverse of T2 values. Variation in voxel R2 values related to the molecular environment and molecular motion within a given voxel (Brown et al. 2014) such as cellular density, myelin content, or water content. R2 values are responsive to changes within healthy brains (Whittall et al. 1997) or certain brain injuries (Assaf et al. 1997) or disease (Briellmann et al. 2002; Fisniku et al. 2008). All R2 maps were warped into the space of a cerebral hemisphere template constructed from the images of 30 representative specimens, first using linear and then nonlinear registration methods.

To obtain the lists of predicted most-affected single gray matter regions (Tables S1, S3) we use the IIT Human Brain Atlas (Varentsova et al. 2014) ( and the regionstat tool to first generate the pairs of gray matter regions most likely connected by white matter fibers traversing through the white matter region of interest, and then derive single gray matter regions with the most streamlines through the white matter region of interest. Specifically, the impact score for a single gray matter region is computed by summing the percentages of streamlines traversing through the white matter region of interest and terminating to that gray matter region. For full details of neuroimaging methods, see Supplemental methods.

Imaging omic maps

The average values for each of the resulting gene sets/molecular system is mapped onto the MRI data of brain scans of the same individuals to identify significantly correlated voxels (Fig. 1). Specifically, we identify all voxels in the cerebral hemisphere template significantly correlated with any module, under a false discovery rate (FDR) of 5%. We further guard against false positives by accepting only clusters of 100 or more contiguous voxels (100 mm3) that all surpass the FDR-corrected critical p-value. The locations with Pearson correlations that pass these criteria define locations where brain microstructure is related to the average level of a given molecular system. This methodology is parallel to standard neuroimaging studies to identify brain regions that are synchronized with the phenotype of interest; in this case the phenotype of interest is the level of gene expression or DNA methylation in various molecular systems.


Identification of brain regions associated with molecular systems

Analogous to imaging genetics studies, we compare the average expression of molecular systems in gene expression and DNA methylation to each neuroimaging voxel to create maps of the brain regions related to these phenotypes. Specifically, we compare coexpression or comethylation modules and brain R2, and observe correlations proximal to the dorsolateral prefrontal cortex, and also in voxels located in distant regions of the brain (Figs. 2a, 3a). The maps of correlations between molecular systems and R2 (Figs. 2a, 3a) indicate where the brain microstructure changes concurrently with the average level of a given molecular system.
Fig. 2

Maps of expression-correlated brain areas

(a) Locations in which ex-vivo transverse relaxation (R2) is correlated with expression of molecular systems related to transcriptional regulation (m109 - red), synaptic transmission (m23 - dark blue), myelination (m110 - green), nuclear processes (m111 - yellow) or unknown processes (m131 - light blue). All colored labels are displayed with 50% transparency to allow for partial visualization of overlapping labels. Critical p-value threshold for expression-correlated voxels determined by correction for multiple comparisons to yield false discovery rate of 0.05 (b) Cortical and subcortical gray matter terminals of white matter pathways traversing through the region with R2 values linked to expression of m109. The blue region comprises voxels for which R2 was significantly associated with the expression of m109, after FDR correction for multiple comparisons, thresholding based on a minimum cluster size of 100 mm3. The red-to-yellow color assigned to each gray matter region indicates the relative proportion of streamlines (a proxy of white matter fiber tracts) traversing the region in blue and terminating to that gray matter region (see also Tables S1, S2)

Fig. 3

Maps of methylation-correlated brain areas

(a) Locations in which ex-vivo transverse relaxation (R2) is correlated with methylation of molecular systems related to cell motility (m66 in blue-green) and a module with unknown functions (m33 in yellow). b Cortical and subcortical gray matter terminals of white matter pathways traversing through the region with R2 values linked to expression of comethylation module m33. c Cortical and subcortical gray matter terminals of white matter pathways traversing through the region with R2 values linked comethylation module m66

Because R2 measurements are most sensitive to changes in white-matter, we integrate atlas-based tractography to associate these changes with gray matter regions that represent the origins or destinations of the white matter fibers (Figs. 2b, 3b, c, Tables S1-S6, see methods). The brain regions likely related to levels of coexpressed molecular systems are primarily located in the frontal cortex, but regions connected via the impacted white matter also include subcortical structures, particularly the putamen (Tables S1, S2, Fig. 2b). The white matter regions associated with comethylation (Fig. 3a) are more extensive (Fig. 4) than those associated with coexpression (Fig. 2a). The gray matter regions predicted to be connected by methylation-associated white matter regions include a comprehensive range of frontal cortex regions (Fig. 3b, Tables S3-S6), as well as some temporal and parietal areas. The relatively unique predicted effects on multiple temporal regions and the precuneus stem from a specific comethyation system associated with cell morphology (Fig. 3, Tables S5, S6).
Fig. 4

Spatial extent and phenotypic correlates of molecular systems in expression and methylation

(a) Comparison of extent of voxel correlations of neuropathologies and a coexpression modules (m109) at an uncorrected p < .01 threshold (solid bars) and a more stringent FDR = 5% threshold (hollow bars). Neuropathology measures are controlled for m109 and m109 is controlled for neuropathologies. b Brain regions associated with neuropathologies and m109. Color-coding matches panel 4A, with AD pathology in dark blue, global infarcts in green, coexpression m109 in red. c Comparison of extent of voxel correlations of neuropathologies and comethylation modules at uncorrected p < .01 threshold (solid bars) and more stringent FDR = 5% threshold (hollow bars). In this comparison, neuropathology measures are controlled for comethylation modules and modules are controlled for neuropathologies. d Brain regions associated with neuropathologies and comethylation modules. Color-coding matches panel 4C, with AD pathology in dark blue, global infarcts in green, comethylation m33 in pink and comethylation m66 in yellow. The distribution and extent of pathology appears to shift between 4B and 4D due to different number of subjects, and different covariates (expression vs methylation) included in model

Functional properties of molecular systems associated with neuroimaging

Although the molecular systems associated with R2 are enriched with a diverse set of molecular functions (Tables S9, S10), despite being derived without reference to any ontology (Tables S8, S9). For instance, the coexpression m109 module is enriched for transcriptional regulatory systems (p < 10−7, Table S9); the m66 comethylation module is enriched for ontology categories generally related to neurogenesis and morphogenesis around synapses (p < 10−5 Table S10). Several modules are highly enriched for specific cell types, such as microglia. However, those most highly enriched cell type modules do not have omic correlations in this dataset (Tables S11, S12). This implies that cell-type specificity is not sufficient to produce imaging omic associations. The lack of cell type enrichment in methylation modules indicates that cell type signatures alone are also not necessary for the existence of imaging omic associations.

In addition to their correlations with R2 values in extensive brain areas, both coexpression module m109 (transcriptional regulation) and comethylation module m66 (synapses and morphogenesis) have significant correlations with a wide range of AD clinical and pathologic phenotypes, including β-amyloid load and tau tangle density, and with AD diagnosis, global cognition and cognitive systems (Fig. 5). The consistency of correlations across multiple subcomponents of cognition, and various assays of AD pathology confirms the robustness of the findings. We also validated the relevance of m109 to AD pathology in vitro by testing the effects of influential genes within the module on Aβ42 levels in astrocyte cultures, showing significant effects for INPPL1 and PLXNB1 (Mostafavi et al. 2018).
Fig. 5

Module-trait associations of modules with neuroimaging correlations.

Full trait descriptions in supplement. Asterisks (*) denote associations significant at FDR of 5%

Comparison to neuroimaging of age-related pathologies

To provide context for the spatial extent and statistical strength of these imaging omic associations, we contrast them with voxels correlating with common neuropathologies (Fig. 4b, d). The number of voxels associated with select molecular systems is commensurate with the number of voxels associated with neuropathology; including those neuropathologies with the strongest relationships with imaging, such as gross infarcts and AD pathology (Fig. 4a, c). While expression-related regions are largely frontal, methylation-associated regions cover both temporal and frontal regions that are typically associated with AD pathology. Because pathological processes have an effect on both omics and brain characteristics, we check to what extent pathology may account for imaging correlations. To do this we account for the effects of all neuropathologies with known large effects on structural imaging: AD, infarcts, and Lewy body disease (Dawe et al. 2014). This reduces the number of voxels associated with m109, but relationships remain numerous, and focused on the same region (Figs. 4a, S1). By contrast, including gene expression in a model of R2 values weakens the associations between R2 and neuropathologic indices such that they do not meet the FDR 5%-corrected significance threshold (Fig. 4a). Therefore, known pathology measures do not account for a substantial proportion of the strongest imaging expression relationship. Similarly accounting for pathology reduces the number of voxels associated with comethylation module m66, but they remain significant and focused in the same region. However, the number of voxels associated with m33 is only slightly reduced when accounting for pathology (Fig. 4c), indicating it represents a non-disease or basic biological relationship between DNA methylation and brain microstructure.

Finally, because m109- and cognition-associated brain regions are semi-overlapping (Fig. S2) we compare the variance in cognitive decline explained by this single module compared to mean R2 values from all voxels that are correlated with cognition. We find that this single coexpression module explains 17% of the variance in cognitive decline and an additional 7% of the variance in cognitive decline above and beyond averaged R2 values of brain regions associated with cognition.


Using brain gene expression, methylation and ex-vivo MRI data from two longitudinal cohort studies of aging, we find molecular systems synchronized with MRI-derived molecular brain characteristics in many brain areas. These imaging-omic associations are spatially extensive and involve hundreds of genes in several molecular systems, including transcriptional regulation and cell morphology. Further, both the molecular systems and the brain regions with which they covary are associated with a wide range of AD clinical and pathologic phenotypes suggesting that both have important functional consequences.

Molecular systems and brain microstructure are independently known to be essential factors in cognitive function and disease susceptibility. The scope and strength of their coordination has been challenging to observe, although glimpses of large-scale coordination have emerged (Fulcher and Fornito 2016; Hibar et al. 2015; Krienen et al. 2016; Richiardi et al. 2015). To date, such studies have focused on comparing distributions of gene expression from one data source with neuroimaging features acquired from another data source. By obtaining omics from the brain paired with neuroimaging from a large cohort we follow the typical neuroimaging approach of identifying brain regions that covary with molecular levels. Our results expand prior work in several important ways.

First, we are able to demonstrate the existence of covariation between two omics and brain structures. The molecular systems are identified without reference to neuroimaging, pathological variables or molecular ontologies; they are produced by the activity of regulatory systems and are highly reproducible (Gaiteri et al. 2014; Mostafavi et al. 2018). The specific MRI measure of R2 characterizes the molecular environment and molecular motion within a given voxel (Brown et al. 2014) such as cellular density, myelin content, or water content. These R2 values are responsive to changes within healthy brains (Whittall et al. 1997), certain brain injuries (Assaf et al. 1997) or disease (Briellmann et al. 2002; Fisniku et al. 2008). As a result, our findings on imaging omic association identify areas of the brain in which expression or methylation of a given molecular system is associated with R2 values and the molecular environment they represent in a given brain area. This also indicates the interoperability of omic and neuroimaging perspectives on brain diseases, particularly within select molecular systems and brain regions.

Second, these imaging omics relationships have a practical influence on AD and likely other neuropathologies and diseases. Here they provide a coherent representation of the molecular and brain integrity progression of AD, prioritizing specific molecular systems as targets, identifying their spatial correlates in the brain, and tracking how these relate to regional correlates of neuropathology and cognition. By bringing together molecular and neuroimaging perspectives on AD it may be possible to merge their strengths as drug development tools and biomarkers for a more efficient perspective on pathogenesis. Thus neuroimaging results are no longer isolated from molecular interventions, but it will be known that structural brain changes in a given region may be controlled by molecular levels nearby or elsewhere in the brain.

Third, we explore the potential biological basis of imaging omic relationships. The causality behind brain omic imaging associations is more complex than that of imaging genetics, as feedback loops, such as activity-driven expression, are pervasive in the brain (West and Greenberg 2011). If omic systems are generally upstream, those molecular systems may be useful in controlling the molecular changes observed through MRI. If they are downstream of these brain changes, the molecular systems mark response to a process in a particular brain area. We explore the possibility that some third factor, such as pathology, may jointly influence brain omics and imaging. However, pathology has limited responsibility for some imaging omic associations and other imaging omic associations persist after controlling for several common neuropathologies. The distribution of cell types is also unlikely to completely account for our findings. Thus, imaging omic relationships appear to have relevance both to disease neurobiology and basic brain function.

The strength of these results is made possible by post-mortem neuroimaging on subjects with multiple brain omics, while their robustness is supported by the large cohort size and many detailed neuropathology and cognitive assessments. These diverse sources of information allow us to explore the basis for synchronization between brain omics and neuroimaging, which may be partially disease-driven, but also disease-independent. Limitations and open questions on the current study include the causality between brain microstructure and the molecular levels assayed by omics, and also questions of the extent of imaging omic relationships in various forms of neuroimaging. As persons in the parent cohorts are currently undergoing ante-mortem imaging, future studies can examine the fMRI associations of omics. Future in-vitro experiments, evaluating cell morphology before and after perturbing key genes in imaging-associated systems, will be helpful in dissecting the causality of imaging omics relationships. Omics data from additional brain regions, or additional types of neuroimaging, may potentially show similar or unique imaging omic association maps.



This work was supported by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG33678, R01AG36042, 1R01AG057911.

Compliance with ethical standards

Conflicts of interest

All authors claim no conflicts of interest.

Research involving Human Participants

The parent cohort studies and substudies were approved by Rush University Medical Center Institutional Review Boards. Participants provided written informed consent and all participants signed an Anatomic Gift Act for brain donation.

Supplementary material

11682_2018_9910_MOESM1_ESM.docx (226 kb)
ESM 1 (DOCX 226 kb)
11682_2018_9910_MOESM2_ESM.xlsx (271 kb)
ESM 2 (XLSX 271 kb)


  1. A Bennett, D., A Schneider, J., Arvanitakis, Z., & S Wilson, R. (2012). Overview and findings from the religious orders study. Current Alzheimer Research, 9(6), 628–645.CrossRefPubMedGoogle Scholar
  2. Arfanakis, K., Wilson, R. S., Barth, C. M., Capuano, A. W., Vasireddi, A., Zhang, S., … Bennett, D. A. (2016). Cognitive activity, cognitive function, and brain diffusion characteristics in old age. Brain Imaging and Behavior, 10(2), 455–463.Google Scholar
  3. Assaf, Y., Beit-Yannai, E., Shohami, E., Berman, E., & Cohen, Y. (1997). Diffusion-and T2-weighted MRI of closed-head injury in rats: a time course study and correlation with histology. Magnetic Resonance Imaging, 15(1), 77–85.CrossRefPubMedGoogle Scholar
  4. Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Beckett, L. A., Aggarwal, N. T., … Bach, J. (2002). Natural history of mild cognitive impairment in older persons. Neurology, 59(2), 198–205.Google Scholar
  5. Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004). Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Archives of Neurology, 61(3), 378–384.CrossRefPubMedGoogle Scholar
  6. Bennett, D. A., Schneider, J. A., Buchman, A. S., Mendes de Leon, C., Bienias, J. L., & Wilson, R. S. (2005). The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology, 25(4), 163–175.CrossRefPubMedGoogle Scholar
  7. Bennett, D. A., Schneider, J. A., Aggarwal, N. T., Arvanitakis, Z., Shah, R. C., Kelly, J. F., … Treinkman, A. D. (2006a). Decision rules guiding the clinical diagnosis of Alzheimer’s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology, 27(3), 169–176.Google Scholar
  8. Bennett, D., Schneider, J., Arvanitakis, Z., Kelly, J., Aggarwal, N., Shah, R., & Wilson, R. (2006b). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology, 66(12), 1837–1844.CrossRefPubMedGoogle Scholar
  9. Bishop, N. A., Lu, T., & Yankner, B. A. (2010). Neural mechanisms of ageing and cognitive decline. Nature, 464(7288), 529–535.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Boyle, P. A., Yu, L., Fleischman, D. A., Leurgans, S., Yang, J., Wilson, R. S., … Bennett, D. A. (2016). White matter hyperintensities, incident mild cognitive impairment, and cognitive decline in old age. Annals of Clinical and Translational Neurology, 3(10), 791–800.Google Scholar
  11. Braskie, M. N., Jahanshad, N., Stein, J. L., Barysheva, M., McMahon, K. L., de Zubicaray, G. I., … Toga, A. W. (2011). Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. Journal of Neuroscience, 31(18), 6764–6770.Google Scholar
  12. Briellmann, R. S., Kalnins, R. M., Berkovic, S. F., & Jackson, G. D. (2002). Hippocampal pathology in refractory temporal lobe epilepsy T2-weighted signal change reflects dentate gliosis. Neurology, 58(2), 265–271.CrossRefPubMedGoogle Scholar
  13. Brown, R. W., Cheng, Y.-C. N., Haacke, E. M., Thompson, M. R., & Venkatesan, R. (2014). Magnetic resonance imaging: physical principles and sequence design: Wiley.Google Scholar
  14. Buchman, A., Boyle, P., Yu, L., Shah, R., Wilson, R., & Bennett, D. (2012). Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology, 78(17), 1323–1329.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Dawe, R. J., Bennett, D. A., Schneider, J. A., Vasireddi, S. K., & Arfanakis, K. (2009). Postmortem MRI of human brain hemispheres: T2 relaxation times during formaldehyde fixation. Magnetic Resonance in Medicine, 61(4), 810–818.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Dawe, R. J., Bennett, D. A., Schneider, J. A., Leurgans, S. E., Kotrotsou, A., Boyle, P. A., & Arfanakis, K. (2014). Ex vivo T 2 relaxation: associations with age-related neuropathology and cognition. Neurobiology of Aging, 35(7), 1549–1561.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Dawe, R. J., Yu, L., Leurgans, S. E., Schneider, J. A., Buchman, A. S., Arfanakis, K., … Boyle, P. A. (2016). Postmortem MRI: a novel window into the neurobiology of late life cognitive decline. Neurobiology of Aging, 45, 169–177.Google Scholar
  18. De Jager, P. L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L. C., Yu, L., … McCabe, C. (2014). Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nature Neuroscience, 17(9), 1156–1163.Google Scholar
  19. Erk, S., Meyer-Lindenberg, A., von Boberfeld, C. O., Esslinger, C., Schnell, K., Kirsch, P., … Witt, S. H. (2011). Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. Journal of Neuroscience, 31(49), 18180–18184.Google Scholar
  20. Fisniku, L., Brex, P., Altmann, D., Miszkiel, K., Benton, C., Lanyon, R., … Miller, D. (2008). Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain, 131(3), 808–817.Google Scholar
  21. Fulcher, B. D., & Fornito, A. (2016). A transcriptional signature of hub connectivity in the mouse connectome. Proceedings of the National Academy of Sciences, 113(5), 1435–1440.CrossRefGoogle Scholar
  22. Gaiteri, C., Ding, Y., French, B., Tseng, G. C., & Sibille, E. (2014). Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders. Genes, Brain and Behavior, 13(1), 13–24.CrossRefGoogle Scholar
  23. Gaiteri, C., Chen, M., Szymanski, B., Kuzmin, K., Xie, J., Lee, C., … Grabowski, T. (2015). Identifying robust communities and multi-community nodes by combining top-down and bottom-up approaches to clustering. Scientific Reports, 5.Google Scholar
  24. Hawrylycz, M., Miller, J. A., Menon, V., Feng, D., Dolbeare, T., Guillozet-Bongaarts, A. L., … Bernard, A. (2015). Canonical genetic signatures of the adult human brain. Nature Neuroscience, 18(12), 1832–1844.Google Scholar
  25. Hibar, D. P., Stein, J. L., Renteria, M. E., Arias-Vasquez, A., Desrivieres, S., Jahanshad, N., … Medland, S. E. (2015). Common genetic variants influence human subcortical brain structures. Nature, 520(7546), 224–229.
  26. Kohannim, O., Hua, X., Rajagopalan, P., Hibar, D. P., Jahanshad, N., Grill, J. D., … Weiner, M. W. (2013). Multilocus genetic profiling to empower drug trials and predict brain atrophy. NeuroImage: Clinical, 2, 827–835.Google Scholar
  27. Kotrotsou, A., Bennett, D. A., Schneider, J. A., Dawe, R. J., Golak, T., Leurgans, S. E., … Arfanakis, K. (2014). Ex vivo MR volumetry of human brain hemispheres. Magnetic Resonance in Medicine, 71(1), 364–374.Google Scholar
  28. Kotrotsou, A., Schneider, J. A., Bennett, D. A., Leurgans, S. E., Dawe, R. J., Boyle, P. A., … Arfanakis, K. (2015). Neuropathologic correlates of regional brain volumes in a community cohort of older adults. Neurobiology of Aging, 36(10), 2798–2805.Google Scholar
  29. Krienen, F. M., Yeo, B. T., Ge, T., Buckner, R. L., & Sherwood, C. C. (2016). Transcriptional profiles of supragranular-enriched genes associate with corticocortical network architecture in the human brain. Proceedings of the National Academy of Sciences, 113(4), E469–E478.CrossRefGoogle Scholar
  30. Langfelder, P., & Horvath, S. (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 9(1), 1.CrossRefGoogle Scholar
  31. Lim, A. S., Klein, H.-U., Yu, L., Chibnik, L. B., Ali, S., Xu, J., … De Jager, P. L. (2017). Diurnal and seasonal molecular rhythms in human neocortex and their relation to Alzheimer’s disease. Nature Communications, 8, 14931.Google Scholar
  32. Mostafavi, S., Gaiteri, C., Sullivan, S., White, C., Takasi, S., Xu, J., … De Jager, P. L. (2018). A molecular network of the aging human brain provides insights into the pathology and manifestations of Alzheimer’s disease. Nature Neuroscience, 21, 811–819. Google Scholar
  33. Munafò, M. R., Brown, S. M., & Hariri, A. R. (2008). Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biological Psychiatry, 63(9), 852–857.CrossRefPubMedGoogle Scholar
  34. Nag, S., Yu, L., Capuano, A. W., Wilson, R. S., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2015). Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Annals of Neurology, 77(6), 942–952.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Ng, B., White, C. C., Klein, H.-U., Sieberts, S. K., McCabe, C., Patrick, E., … Bennett, D. A. (2017). An xQTL map integrates the genetic architecture of the human brain's transcriptome and epigenome. Nature neuroscience, 20(10), nn. 4632.Google Scholar
  36. Numata, S., Ye, T., Hyde, T. M., Guitart-Navarro, X., Tao, R., Wininger, M., … Lipska, B. K. (2012). DNA methylation signatures in development and aging of the human prefrontal cortex. The American Journal of Human Genetics, 90(2), 260–272.Google Scholar
  37. Richiardi, J., Altmann, A., Milazzo, A.-C., Chang, C., Chakravarty, M. M., Banaschewski, T., … Büchel, C. (2015). Correlated gene expression supports synchronous activity in brain networks. Science, 348(6240), 1241–1244.Google Scholar
  38. Schneider, J., Wilson, R., Bienias, J., Evans, D., & Bennett, D. (2004). Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology, 62(7), 1148–1155.CrossRefPubMedGoogle Scholar
  39. Schneider, J., Arvanitakis, Z., Yu, L., Boyle, P., Leurgans, S., & Bennett, D. (2012). Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain, 135(10), 3005–3014.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Stein, J. L., Medland, S. E., Vasquez, A. A., Hibar, D. P., Senstad, R. E., Winkler, A. M., … Bergmann, Ø. (2012). Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 44(5), 552–561.Google Scholar
  41. Varentsova, A., Zhang, S., & Arfanakis, K. (2014). Development of a high angular resolution diffusion imaging human brain template. NeuroImage, 91, 177–186.CrossRefPubMedPubMedCentralGoogle Scholar
  42. Vértes, P. E., Rittman, T., Whitaker, K. J., Romero-Garcia, R., Váša, F., Kitzbichler, M., … Jones, P. (2016). Gene transcription profiles associated with inter-modular hubs and connection distance in human fMRI networks. Philosophical Transactions of the Royal Society of London: Biological Sciences.Google Scholar
  43. Wang, G.-Z., Belgard, T. G., Mao, D., Chen, L., Berto, S., Preuss, T. M., … Konopka, G. (2015). Correspondence between resting-state activity and brain gene expression. Neuron, 88(4), 659–666.Google Scholar
  44. West, A. E., & Greenberg, M. E. (2011). Neuronal activity–regulated gene transcription in synapse development and cognitive function. Cold Spring Harbor Perspectives in Biology, 3(6), a005744.CrossRefPubMedPubMedCentralGoogle Scholar
  45. Whittall, K. P., Mackay, A. L., Graeb, D. A., Nugent, R. A., Li, D. K., & Paty, D. W. (1997). In vivo measurement of T2 distributions and water contents in normal human brain. Magnetic Resonance in Medicine, 37(1), 34–43.CrossRefPubMedGoogle Scholar
  46. Wilson, R. S., Schneider, J. A., Arnold, S. E., Bienias, J. L., & Bennett, D. A. (2007). Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Archives of General Psychiatry, 64(10), 1204–1212.CrossRefPubMedGoogle Scholar
  47. Wilson, R., Leurgans, S., Boyle, P., Schneider, J., & Bennett, D. (2010). Neurodegenerative basis of age-related cognitive decline. Neurology, 75(12), 1070–1078.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Wilson, R. S., Boyle, P. A., Yu, L., Segawa, E., Sytsma, J., & Bennett, D. A. (2015). Conscientiousness, dementia related pathology, and trajectories of cognitive aging. Psychology and Aging, 30(1), 74.CrossRefPubMedPubMedCentralGoogle Scholar
  49. Yu, L., Dawe, R. J., Boyle, P. A., Gaiteri, C., Yang, J., Buchman, A. S., … Bennett, D. A. (2017). Association Between Brain Gene Expression, DNA Methylation, and Alteration of Ex Vivo Magnetic Resonance Imaging Transverse Relaxation in Late-Life Cognitive Decline. JAMA neurology.Google Scholar
  50. Zhang, B., & Horvath, S. (2005). A general framework for weighted gene co-expression network analysis. Statistical Applications in Genetics and Molecular Biology, 4(1), 1128.CrossRefGoogle Scholar
  51. Zhang, P., Qin, W., Wang, D., Liu, B., Zhang, Y., Jiang, T., & Yu, C. (2015). Impacts of PICALM and CLU variants associated with Alzheimer’s disease on the functional connectivity of the hippocampus in healthy young adults. Brain Structure and Function, 220(3), 1463–1475.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2018

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Chris Gaiteri
    • 1
    Email author
  • Robert Dawe
    • 1
    • 2
  • Sara Mostafavi
    • 3
  • Katherine D. Blizinsky
    • 1
    • 4
  • Shinya Tasaki
    • 1
  • Vitalina Komashko
    • 1
  • Lei Yu
    • 1
  • Yanling Wang
    • 1
  • Julie A. Schneider
    • 1
  • Konstantinos Arfanakis
    • 1
    • 2
    • 5
  • Philip L. De Jager
    • 6
  • David A. Bennett
    • 1
  1. 1.Rush Alzheimer’s Disease CenterRush University Medical CenterChicagoUSA
  2. 2.Department of Diagnostic Radiology and Nuclear MedicineRush University Medical CenterChicagoUSA
  3. 3.Department of Statistics, Department of Medical GeneticsUniversity of British ColumbiaVancouverCanada
  4. 4.National Institutes of HealthNational Human Genome Research InstituteBethesdaUSA
  5. 5.Department of Biomedical EngineeringIllinois Institute of TechnologyChicagoUSA
  6. 6.Columbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations